Forbion European Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. It intends to identify opportunities in the life sciences industry in Europe. The company was incorporated in 2021 and is based in Wilmington, Delaware.
IPO Year: 2022
Exchange: NASDAQ
Website: https://forbion.com/en/feac/
| Date | Price Target | Rating | Analyst |
|---|
15-12G - Forbion European Acquisition Corp. (0001874495) (Filer)
8-K - Forbion European Acquisition Corp. (0001874495) (Filer)
25-NSE - Forbion European Acquisition Corp. (0001874495) (Subject)
10-Q - Forbion European Acquisition Corp. (0001874495) (Filer)
8-K - Forbion European Acquisition Corp. (0001874495) (Filer)
DEFA14A - Forbion European Acquisition Corp. (0001874495) (Filer)
DEFM14A - Forbion European Acquisition Corp. (0001874495) (Filer)
8-K - Forbion European Acquisition Corp. (0001874495) (Filer)
425 - Forbion European Acquisition Corp. (0001874495) (Subject)
8-K - Forbion European Acquisition Corp. (0001874495) (Filer)
BOSTON and MONTREAL, Sept. 7, 2023 /PRNewswire/ - enGene, Inc., a clinical-stage biotechnology company mainstreaming gene therapy through its novel platform for the delivery of therapeutics to mucosal tissues and other organs, today announced the appointment of Richard Bryce, MBChB, MRCGP, MFPM as its Chief Medical Officer, effective September 19, 2023. Dr. Bryce will oversee the clinical development of EG-70, enGene's lead product candidate for non-muscle invasive bladder cancer (NMIBC), as well as the development strategy for enGene's therapeutic pipeline of tissue-targeted non-viral gene therapies.
Leading institutional investors commit $135 million USD in transaction financing, anchored by FEAC's sponsor, Forbion Growth Sponsor FEAC I B.V. (together with its parent entity Forbion Growth Opportunities Fund I Cooperatief U.A., "Forbion Growth").enGene is a clinical-stage biotechnology company developing non-viral gene therapies based on its proprietary dually derivatized chitosan ("DDX") platform that are re-dosable, manufacturable at scale and designed to be seamlessly integrated into community clinical practices across the globe.Net proceeds are expected to be used to finance enGene's operations through multiple potential value inflection milestones towards a potential Biologics Licen
BASEL, Switzerland, Dec. 09, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG ("VectivBio") (NASDAQ:VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, announced today that Wouter Joustra was elected as a new member of the Board of Directors at the Extraordinary General Meeting held on December 9, 2022. Mr. Wouter Joustra brings a breadth of capital markets and investment experience in the life sciences investment industry to VectivBio. He joined Forbion, a leading European life sciences venture capital firm, in October 2019, where he is currently General Partner. At Forbion, Mr. Joustra is responsible for deal originatio
BOSTON and MONTREAL, Sept. 7, 2023 /PRNewswire/ - enGene, Inc., a clinical-stage biotechnology company mainstreaming gene therapy through its novel platform for the delivery of therapeutics to mucosal tissues and other organs, today announced the appointment of Richard Bryce, MBChB, MRCGP, MFPM as its Chief Medical Officer, effective September 19, 2023. Dr. Bryce will oversee the clinical development of EG-70, enGene's lead product candidate for non-muscle invasive bladder cancer (NMIBC), as well as the development strategy for enGene's therapeutic pipeline of tissue-targeted non-viral gene therapies.
4 - Forbion European Acquisition Corp. (0001874495) (Issuer)
4 - Forbion European Acquisition Corp. (0001874495) (Issuer)
3/A - Forbion European Acquisition Corp. (0001874495) (Issuer)
3/A - Forbion European Acquisition Corp. (0001874495) (Issuer)
SC 13G/A - Forbion European Acquisition Corp. (0001874495) (Subject)
SC 13G - Forbion European Acquisition Corp. (0001874495) (Subject)
SC 13G/A - Forbion European Acquisition Corp. (0001874495) (Subject)
SC 13G/A - Forbion European Acquisition Corp. (0001874495) (Subject)
SC 13G/A - Forbion European Acquisition Corp. (0001874495) (Subject)
SC 13G - Forbion European Acquisition Corp. (0001874495) (Subject)
SC 13G - Forbion European Acquisition Corp. (0001874495) (Subject)
SC 13G/A - Forbion European Acquisition Corp. (0001874495) (Subject)
SC 13G - Forbion European Acquisition Corp. (0001874495) (Subject)
SC 13D - Forbion European Acquisition Corp. (0001874495) (Subject)
Gainers Miromatrix Medical Inc. (NASDAQ:MIRO) shares climbed 230.7% to $3.3401 after United Therapeutics agreed to acquire the company for $3.25 per share in cash. Eargo, Inc. (NASDAQ:EAR) shares climbed 50.4% to $2.5274 after the company announced it will be taken private by Patient Square Capital. VYNE Therapeutics Inc. (NASDAQ:VYNE) gained 39.9% to $3.1399 after the company announced a private placement of $88 million and data from its Phase 1b trial evaluating once-daily dosing of VYN201 in patients with nonsegmental vitiligo. Conduit Pharmaceuticals Inc. (NASDAQ:CDT) shares gained 27.9% to $1.3042 after falling more than 12% on Friday. HeartCore Enterprises, Inc. (NASDAQ:HTCR)
Gainers Abri SPAC I, Inc. (NASDAQ:ASPA) shares climbed 127.1% to $28.39. Abri's stockholders approved its proposed business combination with DLQ. Nuvve Holding Corp. (NASDAQ:NVVE) shares climbed 88% to $0.2789 after falling 10% on Tuesday. Nuvve recently announced pricing of a $1 million underwritten public offering of roughly 7 million shares of common stock at a price to the public of $0.14 per share. BIO-key International, Inc. (NASDAQ:BKYI) surged 57% to $0.30. BIO-key International reported results for its third quarter ended Sept. 30, 2023. ReShape Lifesciences Inc. (NASDAQ:RSLS) gained 44.7% to $0.2976 after gaining over 6% on Tuesday. ReShape Lifesciences recently announced p
enGene, Inc. (“enGene”), a clinical-stage biotechnology company pioneering novel non-viral gene therapies for local administration into mucosal tissues, and Forbion European Acquisition Corp. ((&ldquo, FEAC, &rdquo, NASDAQ:FRBN), a special purpose acquisition company, today announced that they have entered into a definitive business combination agreement. Upon closing of the transaction, the combined company will be named “enGene Holdings Inc.” whose common shares are expected to be listed on Nasdaq. The financing for the transaction includes Forbion Growth’s existing investment in FEAC Class A shares of $20 million and a PIPE investment, other private investment and non-redemption commitmen